Streetbeat News

Products Services

LGVN

Longeveron Inc (NASDAQ: LGVN) presented positive Phase 2a clinical trial data for its Alzheimer's treatment, Lomecel-B, at the Alzheimer's Association International Conference. The trial met its primary safety and secondary efficacy endpoints, showing potential in slowing disease progression and improving cognitive and functional outcomes. The FDA recently granted RMAT designation to Lomecel-B. LGVN stock is up 22.10% in premarket trading.

Portfolio Pulse from Vandana Singh

July 29, 2024 | 12:35 pm

DIS

IMAX

Disney/Marvel's Deadpool & Wolverine sets IMAX records with a $36.5M global debut, achieving the biggest R-rated and July opening, the eighth biggest IMAX opening ever, and the biggest since Avatar: The Way of Water.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:34 pm

SER

Serina Therapeutics (NYSE:SER) will present data on its POZ-lipid technology at the 4th mRNA-Based Therapeutics Summit, highlighting its potential to enhance the safety and efficacy of mRNA-LNP formulations by avoiding anti-PEG antibody responses.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:32 pm

OSIS

OSI Systems' Security Division has received a $10 million order from an international customer for its Z Backscatter Van Inspection Systems. The order includes maintenance, training, and support for border customs applications.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:31 pm

HSAI

Hesai Technology has entered a strategic partnership with Westwell to provide lidar solutions for autonomous driving, industrial robots, heavy machinery, and smart cities.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:31 pm

ETHA

ETHE

FBTC

GBTC

IBIT

Bitcoin surged to $69,670, nearing $70,000, driven by former President Trump's declaration to make it a national strategic asset if re-elected. The broader crypto market also saw gains, with Ethereum, Solana, and others rising. Bitcoin spot ETFs saw substantial inflows, particularly BlackRock's ETF, while Grayscale's experienced outflows. Ethereum ETFs had mixed results.

Portfolio Pulse from Murtuza Merchant

July 29, 2024 | 12:29 pm

PFE

Pfizer Inc. (NYSE:PFE) is set to release its Q2 earnings, with analysts expecting a drop in EPS from 67 cents to 46 cents, but a slight increase in revenue to $13.02 billion. The European Commission has approved Pfizer's gene therapy DURVEQTIX for hemophilia B. Pfizer's dividend yield stands at 5.46%, translating to a quarterly dividend of 42 cents per share. Investors would need approximately $109,880 worth of Pfizer shares to earn $500 monthly from dividends.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 12:25 pm

HMC

NSANY

TSLA

Nissan has significantly reduced production at its Kyushu plant in Japan due to falling demand in the U.S. market. The company is struggling with high inventory levels and a lack of hybrid models, which has led to missed opportunities in the growing hybrid vehicle market. This follows a period of poor financial performance and a reduction in its full-year outlook.

Portfolio Pulse from Benzinga Neuro

July 29, 2024 | 12:24 pm

ABT

EZPW

GPRK

IART

ICL

IMMP

IOVA

NAMS

PDD

Several major stocks, including Abbott Laboratories, Integra LifeSciences, and NewAmsterdam Pharma, experienced significant declines in Monday's pre-market session. Abbott fell due to a $495 million damages order, Integra LifeSciences dropped after lowering its FY24 outlook, and NewAmsterdam Pharma declined following Phase 3 trial results.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 12:24 pm

BITF

BITO

CLSK

COIN

IBIT

MARA

RIOT

Portfolio Pulse from Anusuya Lahiri

July 29, 2024 | 12:23 pm